Xenopsin-related peptide-1 had not gathered any attention as a subject of the gynecological endocrinology research until 2017, when Temur et al. considered XP-1 as a potential biomarker of insulin resistance in PCOS subjects [32]. The gene discussed is XPA; the disease is polycystic ovary syndrome.